Broadwood Capital Inc buys $96,502,541 stake in STAAR Surgical Company (STAA)

STAAR Surgical Company (STAA) : Broadwood Capital Inc scooped up 437,509 additional shares in STAAR Surgical Company during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 10,855,179 shares of STAAR Surgical Company which is valued at $96,502,541.STAAR Surgical Company makes up approximately 16.43% of Broadwood Capital Inc’s portfolio.

Other Hedge Funds, Including , Ardsley Advisory Partners reduced its stake in STAA by selling 18,612 shares or 19.88% in the most recent quarter. The Hedge Fund company now holds 75,000 shares of STAA which is valued at $666,750. STAAR Surgical Company makes up approx 0.12% of Ardsley Advisory Partners’s portfolio.Kennedy Capital Management boosted its stake in STAA in the latest quarter, The investment management firm added 53,472 additional shares and now holds a total of 202,902 shares of STAAR Surgical Company which is valued at $1,803,799. STAAR Surgical Company makes up approx 0.03% of Kennedy Capital Management’s portfolio.Geode Capital Management boosted its stake in STAA in the latest quarter, The investment management firm added 19,019 additional shares and now holds a total of 212,952 shares of STAAR Surgical Company which is valued at $1,893,143.California State Teachers Retirement System boosted its stake in STAA in the latest quarter, The investment management firm added 1,684 additional shares and now holds a total of 83,932 shares of STAAR Surgical Company which is valued at $556,469.

STAAR Surgical Company closed down -0.07 points or -0.80% at $8.71 with 63,279 shares getting traded on Thursday. Post opening the session at $8.77, the shares hit an intraday low of $8.55 and an intraday high of $8.77 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, STAAR Surgical Company reported $-0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.04. The company had revenue of $20.97 million for the quarter, compared to analysts expectations of $19.91 million. The company’s revenue was up 12.4% compared to the same quarter last year.

Many Wall Street Analysts have commented on STAAR Surgical Company. The Benchmark Company Upgraded STAAR Surgical Company on May 18, 2016 to ” Buy”, Price Target of the shares are set at $6.

STAAR Surgical Company designs develops manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company’s principal products are intraocular lenses (IOLs) and implantable Collamer lenses (ICLs). IOLs are prosthetic intraocular lenses used to restore vision that has been adversely affected by cataracts and include the Company’s lines of silicone and Collamer IOLs and the Preloaded Injector (a silicone or acrylic IOL preloaded into a single-use disposable injector). ICLs consisting of the Company’s ICL and Toric implantable collamer lenses (TICL) are intraocular lenses used to correct refractive conditions such as myopia (near-sightedness) hyperopia (far-sightedness) and astigmatism. The Company operates under the brands STAAR Visian Collamer CentraFLOW AquaPORT nanoFLEX nanoPOINT Epiphany and AquaFlow. Collamer is the brand name for its collagen copolymer lens material.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

STAAR Surgical Company - Is it time to Sell?

Top Brokerage Firms are advising their investors on STAAR Surgical Company. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.